Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate muscle atrophy via the miR-132-3p/FoxO3 axis.

Huihui Ma, Yujie Jing, Jiangping Zeng, Jiaying Ge, Siqi Sun, Ran Cui, Chunhua Qian, Shen Qu, Hui Sheng

Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China. · pubmed

Paper

Abstract

Muscle atrophy or sarcopenia is the loss of muscle mass and strength and leads to an increased risk of disability and death including osteoporotic fractures. Currently, there are no available clinical biologic agents for the treatment of sarcopenia. Since exosomes have become increasingly attractive as a novel therapeutic approach due to their ability to facilitate cell-cell transfer of proteins and RNAs, promoting cell repair and function recovery, we hypothesized that human umbilical cord mesenchymal stem cell-derived exosomes (hucMSC-Exos) might benefit muscle atrophy in age-related and dexamethasone-induced sarcopenia animal models.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper addresses muscle atrophy, a condition associated with aging, and explores a potential therapeutic approach using exosomes derived from human umbilical cord mesenchymal stem cells. While it contributes to understanding a mechanism related to age-related muscle loss, it primarily focuses on treatment rather than addressing the root causes of aging. Thus, it represents solid research but with limited impact on the broader field of longevity.

Author of this paper? Send a correction.